Subscribe: MedWorm: Transfusion Therapy
Added By: Feedage Forager Feedage Grade B rated
Language: English
blood  company  funding  health  hemanext  medical  medworm  million  patients  platelet  study  therapy  transfusion therapy  transfusion 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: MedWorm: Transfusion Therapy

MedWorm: Transfusion Therapy News provides a medical RSS filtering service. Thousands of medical RSS feeds are combined and output via different filters. This feed contains the latest news in Transfusion Therapy

Last Build Date: Wed, 20 Dec 2017 21:17:22 +0100


Bethesda transfusion therapy company raises $2.7 million

Wed, 20 Dec 2017 19:42:11 +0100

A Bethesda medical technology company focused on developing innovations in the transfusion industry has raised $2.7 million in an equity funding round. Hemanext, which changed its corporate name in October from New Health Sciences Inc., was seeking to raise a total of $5 million, a Securities and Exchange Commission filing shows. Hemanext did not specify was the proceeds of the funding will be used for. I've reached out to Hemanext for comment a nd will update this story when I hear back. The company… (Source: Health Care:Physician Practices headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

Terumo launches Mirasol pathogen reduction tech trial

Wed, 17 May 2017 16:21:52 +0100

This study is intended as a step towards improving transfusion therapy and transfusion safety in the U.S. We’re excited to be a part of this study that hopefully will lead to measures that could further protect the nation’s blood supply from certain complications and threats of blood transfusions,” Miplate lead investigator Dr. Sherrill Slichter of Bloodworks Northwest said in a prepared statement. The study is expected to take 3.5 years and will include involvement from up to 15 hospitals and blood centers as well as 556 patients, the company said. Eligible patients in the trial will have a platelet count of less than or equal to 10,000/µL, and require at least 2 platelet transfusions. “In addition to being designed to support our PMA application for U.S. approv...